Rationale for Development of New Oral Anticoagulants

Author(s): Muharrem Akin, Julian Widder, Ibrahim Akin, Michael Brehm, Andreas Schäfer

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
Formerly Current Drug Targets - Cardiovascular & Hematological Disorders

Volume 15 , Issue 2 , 2015

Become EABM
Become Reviewer
Call for Editor


The development of new or direct oral anticoagulants was triggered by the disadvantages of classic oral anticoagulation, which was isolated in Link’s laboratory in 1940. Some of these limitations are the individual variation in response to these drugs, drug interaction and the need for regular laboratory monitoring. With increasing comorbidity and life expectancy in populations these limitations led to interruption of treatment or even underuse of treatment in light of potential side effects. With the introduction of novel oral anticoagulants some of these drawbacks are targeted whereas even these drugs also have some limitations and should be given with cautions and not to all patients having an indication for anticoagulation.

Keywords: Coumadin, novel oral anticoagulation, thrombembolism, warfarin.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [89 - 91]
Pages: 3
DOI: 10.2174/1871529X1502151209110044
Price: $65

Article Metrics

PDF: 49
PRC: 1